U023 Behind the Bra: What Dermatologists Should Know About Diseases of the Breast
DESCRIPTION
Breast dermatoses, including inflammatory, infectious, and neoplastic entities, are common yet frequently underrecognized. This case-based session delivers a practical approach to high-yield diagnoses. We will review breast changes during pregnancy and lactation and evaluation of breastfeeding patients with nipple pain, with emphasis on medication safety in pregnancy and lactation. Idiopathic granulomatous mastitis will be discussed, including presentation, comorbidities, and treatment. We will also highlight cutaneous manifestations of breast cancer and radiation-related skin changes to improve early recognition. Dermatologic considerations in transgender and non-binary patients, including surgical complications and the effects of gender-affirming hormone therapy, will also be addressed.
LEARNING OBJECTIVES
Differentiate and treat common inflammatory, infectious, and neoplastic breast dermatoses using a case-based diagnostic approach.
Evaluate breast changes during pregnancy and lactation, including causes of nipple pain, with attention to medication safety in these populations.
Recognize cutaneous manifestations of breast malignancy and treatment-related changes that warrant biopsy, referral, or multidisciplinary care.
SCHEDULE
7:30 AM
Inflammatory and immune-mediated diseases of the breast
Emily R. Nadelmann, MD, FAAD
7:45 AM
Malignancy of the breast and radiation-related skin changes
Grace Y. Kim, MD, FAAD
8:00 AM
Infections of the breast and dermatologic considerations in transgender and non-binary patients
Paige Adams, MD
8:15 AM
The breast in pregnancy and lactation
Jenny Eileen Murase, MD, FAAD
DIRECTOR
Jenny Eileen Murase, MD, FAAD
PAFMG/UCSF
SPEAKERS
Paige Adams, MD
Grace Y. Kim, MD, FAAD
University of California San Diego
Emily R. Nadelmann, MD, FAAD
DISCLOSURES
Paige Adams, MD
No financial relationships exist with ineligible companies.
Grace Y. Kim, MD, FAAD
No financial relationships exist with ineligible companies.
Jenny Eileen Murase, MD, FAAD
AbbVie – Consultant(Honoraria), Speaker/Faculty Education(Honoraria); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Attovia Therapeutics – Consultant (1099 relationship)(Honoraria); Blueprint Medicines – Advisory Board(Honoraria); Blueprints Medicine – Speaker(Honoraria); Eli Lilly – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker/Faculty Education(Honoraria); Galderma – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); Leo Pharma Inc – Speaker/Faculty Education(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Speaker(Honoraria); Phothera – Advisory Board(Honoraria); Regeneron – Speaker/Faculty Education(Honoraria); Sanofi – Speaker(Honoraria); Sanofi/Regeneron – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); UCB – Advisory Board(Honoraria), Consultant(Honoraria), Speaker/Faculty Education(Honoraria); UpToDate – Consultant(Honoraria);
Emily R. Nadelmann, MD, FAAD
No financial relationships exist with ineligible companies.